[1] [1] CHIU M L, LUO S T, CHEN Y Y, et al. Establishment of Asia- Pacific network for enterovirus surveillance［J］. Vaccine, 2020, 38( 1): 1-9.

[2] [2] TOMATIS SOUVERBIELLE C, ERDEM G, SáNCHEZ P J. Up date on nonpolio enterovirus and parechovirus infections in neo- nates and young infants［J］. Current Opinion in Pediatrics, 2023, 35(3): 380-389.

[3] [3] WANG Y, ZHAO H, OU R, et al. Epidemiological and clinical characteristics of severe hand-foot-and-mouth disease (HFMD) among children: a 6-year population-based study［J］. BMC Public Health, 2020, 20( 1): 801.

[4] [4] SOUSA JUNIOR I P, VIEIRA T C R G. Enterovirus infection and its relationship with neurodegenerative diseases［J］. Memorias Do Instituto Oswaldo Cruz, 2023, 118: e220252.

[5] [5] YU L, HE J, WANG L, et al. Inflammatory profiles revealed the dysregulation of cytokines in adult patients of HFMD［J］. Interna- tional Journal of Infectious Diseases, 2019, 79: 12-20.

[6] [6] HONG J, LIU F, QI H, et al. Changing epidemiology of hand, foot, and mouth disease in China, 2013―2019: a population- based study［J］. Lancet Regional Health - Western Pacific, 2022, 20: 100370.

[7] [7] ZHANG Jing, LI Xiuhui, LI Li, et al. Etiology and epidemiology of hand, foot and mouth disease in China［J］. Chinese Journal of Epidemiology, 2022, 43(5): 771-783.

[8] [8] ZHU P, JI W, LI D, et al. Current status of hand-foot-and-mouth disease［J］. Journal of Biomedical Science, 2023, 30( 1): 15.

[9] [9] WANG J, LIU J, FANG F, et al. Genomic surveillance of cox- sackievirus A10 reveals genetic features and recent appearance of genogroup D in Shanghai, China, 2016―2020［J］. Virologica Sinica, 2022, 37(2): 177-186.

[10] [10] YANG Q , LIU F, CHANG L , et al. Molecular epidemiology and clinical characteristics of enteroviruses associated HFMD in Chengdu, China, 2013―2022［J］. Virology Journal, 2023, 20( 1): 202.

[11] [11] BIAN L, GAO F, MAO Q, et al. Hand, foot, and mouth disease as- sociated with coxsackievirus A10: more serious than it seems［J］. Expert Review ofAnti-infective Therapy, 2019, 17(4): 233-242.

[12] [12] CHEN M, HE S, YAN Q, et al. Severe hand, foot and mouth dis- ease associated with coxsackievirus A10 infections in Xiamen, China in 2015［J］. Journal of Clinical Virology, 2017, 93: 20-24.

[13] [13] ZHANG J, XU D, LIU H, et al. Characterization of coxsackievi- rus A10 strains isolated from children with hand, foot, and mouth disease［J］. Journal of Medical Virology, 2022, 94(2): 601-609.

[14] [14] MALONIS R J, LAI J R, VERGNOLLE O. Peptide-based vac- cines: current progress and future challenges［J］. Chemical Re- views, 2020, 120(6): 3210-3229.

[15] [15] ZHOU X, JIANG X, QU M, et al. Engineering antiviral vaccines ［J］. ACS Nano, 2020, 14( 10): 12370-12389.

[16] [16] ZHU L, SUN Y, FAN J, et al. Structures of coxsackievirus A10 unveil the molecular mechanisms of receptor binding and viral uncoating［J］. Nature Communications, 2018, 9( 1): 4985.

[17] [17] CHEN J, YE X, ZHANG X Y, et al. Coxsackievirus A10 atomic structure facilitating the discovery of a broad-spectrum inhibitor against human enteroviruses［J］. Cell Discovery, 2019, 5: 4.

[18] [18] ZHAO Y, ZHOU D, NI T, et al. Hand-foot-and-mouth disease vi- rus receptor KREMEN1 binds the canyon of coxsackie virus A10 ［J］. Nature Communications, 2020, 11( 1): 38.

[19] [19] GAO F S, FENG L, JIANG P, et al. Expression, purification, crystallization and preliminary X-ray diffraction analysis of swine leukocyte antigen 2 complexed with a CTL epitope AS64 derived from Asia1 serotype of foot-and-mouth disease virus［J］. BMC Veterinary Research, 2018, 14( 1): 407.

[20] [20] TIT-OON P, THARAKARAMAN K , ARTPRADIT C , et al. Prediction of the binding interface between monoclonal antibody m102.4 and Nipah attachment glycoprotein using structure-guided alanine scanning and computational docking［J］. Scientific Re- ports, 2020, 10( 1): 18256.

[21] [21] ZHANG J, HUANG H, XU L, et al. Screening and identification of linear B cell epitopes within the nonstructural proteins of en- terovirus 71［J］. Viral Immunology, 2019, 32(2): 84-88.

[22] [22] FENG Hongsheng, JIN Hang, GAO Yongyu, et al. Application of immunoinformatics in epitope vaccine development［J］. China Biotechnology, 2023, 43(7): 88-100.

[23] [23] ASSMUS L M, GUAN J, WU T, et al. Overlapping peptides elicit distinct CD8+ T cell responses following influenza A virus infec- tion［J］. Journal of Immunology, 2020, 205(7): 1731-1742.

[24] [24] TSUJI K, OWUSU K B A, KOBAYAKAWA T, et al. Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment［J］. Bioorganic & Medicinal Chemistry, 2020, 28( 11): 115488.

[25] [25] OLVERA A, NOGUERA-JULIAN M, KILPELAINEN A, et al. SARS-CoV-2 consensus-sequence and matching overlapping pep- tides design for COVID19 immune studies and vaccine develop- ment［J］. Vaccines (Basel), 2020, 8(3): 444.

[26] [26] JI T, GUO Y, HUANG W, et al. The emerging sub-genotype C2 of coxsackievirus A10 associated with hand, foot and mouth disease extensively circulating in mainland of China［J］. Scientific Re- ports, 2018, 8( 1): 13357.

[27] [27] ZENG Qing, LIU Jingwen, GENG Jinmei, et al. Genetic char- acteristics of VP1 region of coxsackievirus A10 in Guangzhou ［J］. Journal of Preventive Medicine Information, 2022, 38(9): 1243-1248.

[28] [28] WANG J, LIU H, CAO Z, et al. Epidemiology of hand, foot, and mouth disease and genetic evolutionary characteristics of cox- sackievirus A10 in Taiyuan City, Shanxi Province from 2016 to 2020［J］. Viruses, 2023, 15(3): 694.

[29] [29] JIN W P, LU J, ZHANG X Y, et al. Efficacy of coxsackievirus A5 vaccine candidates in an actively immunized mouse model［J］. Journal ofVirology, 2021, 95(6): e01743-20.

[30] [30] DIAO H, LU Y, LING Y, et al. Peptide-based self-assembly: de- sign, bioactive properties, and its applications［J］. Current Phar- maceutical Design, 2023, 29(9): 640-651.

[31] [31] ZAHEDIPOUR F, JAMIALAHMADI K, ZAMANI P, et al. Im- proving the efficacy of peptide vaccines in cancer immunotherapy ［J］. International Immunopharmacology, 2023, 123: 110721.

[32] [32] KHALAJ-HEDAYATI A , CHUA C L L , SMOOKER P, et al. Nanoparticles in influenza subunit vaccine development: immuno- genicity enhancement［J］. Influenza Other Respir Viruses, 2020, 14( 1): 92-101.

[33] [33] XIA Xin, ZHU Yawen, ZHOU Li, et al. Research and mecha- nisms of action of novel vaccine adjuvants: a literature review ［J］. Chinese Journal of Vaccines and Immunization, 2023, 29(4): 474-482.